Skip to main content
Provectus Algae banner
Provectus Algae logo

Provectus Algae

Provectus Algae is a biotechnology company specializing in the optimization of algae to produce high-value chemicals and biologics.

Backed by

At One VenturesAt One Ventures
Hitachi VenturesHitachi Ventures
Australian GovernmentAustralian Government
Mort & CoMort & Co
Methane MitigationMethane Mitigation

Raised 12.6M SERIES_A on July 23, 2025

About

Provectus Algae runs an automated, closed Precision Photosynthesis platform that programs microalgae with AI, robotics and controlled lighting to produce specialty ingredients and algae-based animal feed and food.

Mission

Provectus Algae uses its proprietary Precision Photosynthesis® and AI‑enabled biomanufacturing platform to discover, develop, and produce algae products at scale. Its first commercial product, Surf'N'Turf®, is an algae‑based feed supplement for ruminant livestock that includes a seaweed shown to improve rumen digestion and reduce methane from enteric fermentation. The company integrates research, development, and production to control expression of target compounds for step‑changes in productivity and cost of goods. Provectus positions its platform for applications across agriculture, personal care, and other industries while emphasizing scalable, carbon‑negative solutions. Recent financing strengthens its balance sheet to scale manufacturing and accelerate commercial deployment of Surf'N'Turf. Provectus Algae is a biotechnology company that programs microalgae to produce specialty ingredients using its Precision Photosynthesis™ platform and a synthetic biology stack. The company focuses on photosynthesis‑based, carbon‑capturing biomanufacturing to deliver high‑performance, sustainable products that can complement fermentation‑based platforms. Provectus says its technologies enable production of valuable biochemicals and aims to make photosynthetic bioprocesses commonplace across the life science sector. The company received an undisclosed strategic investment from CJ BIO to accelerate commercialization of its specialty ingredients. Provectus expects to gain access to CJ BIO’s experience in scale‑up, process automation, and large‑scale biomolecule production as part of the partnership. The company is based in Noosaville, Australia. Provectus Algae is an Australian synthetic biology firm that programs microalgae to produce specialty and biosynthetic ingredients via its Precision Photosynthesis® platform. The company has developed a 24/7 automated closed-system biomanufacturing platform designed to move products from ideation to industry scale with continuity of production technology. Its current pipeline includes recombinant proteins and a suite of natural products, one of which already has a commercial agreement with a leading food and beverage ingredients supplier. Provectus plans to use new funding to expand its sustainable biomanufacturing platform, accelerate R&D and early-stage product development capabilities, and increase commercial production capacity. The technology converts carbon dioxide and light into high-value products and is positioned to address supply-chain challenges by offering end-to-end product development to large-scale biomanufacturing for corporate customers. Provectus Algae develops algae-based products and specialty ingredients for the food, agriculture and animal health sectors. The company operates a biotech foundry in Noosa Heads, Queensland, and uses a platform called Precision Photosynthesis that combines proprietary lighting, robotics and artificial intelligence to “program” algae by controlling CO2, nitrogen and other inputs. Provectus reports its first prototype increased production 20% and reduced operating costs 30%, while a second prototype raised productivity by 200%, enabling scale-up and production of natural, clean-label products. The startup has signed a commercial partnership with one of the world’s top five food and beverage companies and is initially targeting markets that reduce barriers to entry. Longer-term plans include producing biosynthetic compounds, therapeutic ingredients and environmentally friendlier agricultural products using genetic engineering and gene-editing tools like CRISPR, contingent on regulatory development. Founder and CEO Nusqe Spanton draws on experience in the pearl oyster industry in Indonesia and aims to optimize a wide range of algae species to unlock diverse commercial applications.

Quick Facts

Founded

2018

Funding

SERIES_A

Industry

Animal Feed, Biotechnology, Cosmetics, Food and Beverage, GreenTech, Sustainability, Therapeutics

Team Size

11-50

Headquarters

Noosaville, Queensland, Australia